The role of BRCA mutation testing in determining breast cancer therapy (Q37808102)

23 August 2017

The role of BRCA mutation testing in determining breast cancer therapy (English)

1 reference

23 August 2017

1 reference

6

1 reference

23 August 2017

4

Bettina Meiser

1 reference

23 August 2017

Alison H Trainer

1

1 reference

23 August 2017

Craig R Lewis

series ordinal

2

1 reference

23 August 2017

Kathy Tucker

series ordinal

3

1 reference

23 August 2017

Michael Friedlander

series ordinal

5

1 reference

23 August 2017

language of work or name

English

0 references

publication date

9 November 2010

1 reference

Nature Reviews Clinical Oncology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

12

1 reference

23 August 2017

708-717

1 reference

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Update on the Manchester Scoring System for BRCA1 and BRCA2 testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Evaluation of models to predict BRCA germline mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Limited family structure and BRCA gene mutation status in single cases of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

A high proportion of founder BRCA1 mutations in Polish breast cancer families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Molecular portraits of human breast tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Triple negative tumours: a critical review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Triple-negative breast cancer: therapeutic options

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Incorporating tumour pathology information into breast cancer risk prediction algorithms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Optimal selection of individuals for BRCA mutation testing: a comparison of available methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival and prognostic factors in BRCA1-associated breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Is breast-conserving therapy in the genetically predisposed breast cancer patient a reasonable and appropriate option?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy inBRCA1/2-Associated Stage I/II Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival in hereditary breast cancer associated with germline mutations of BRCA2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

31 March 2020

12 December 2020

Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Familial breast cancer: an investigation into the outcome of treatment for early stage disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prophylactic mastectomy for the prevention of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival and recurrence after breast cancer in BRCA1/2 mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival and tumor characteristics of German hereditary breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prognosis and clinical presentation of BRCA2-associated breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

BRCA-associated breast cancer in young women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Familial invasive breast cancers: worse outcome related to BRCA1 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics,BRCAmutations and oophorectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Homologous repair of DNA damage and tumorigenesis: the BRCA connection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Molecular pathogenesis of Fanconi anemia: recent progress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Biallelic inactivation of BRCA2 in Fanconi anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Meta-analysis of BRCA1 and BRCA2 penetrance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Managing hereditary ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up ofBRCA1Mutation Carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.175

Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes

31 March 2020

1 reference

PubMed

12 December 2020

BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis

1 reference

PubMed

12 December 2020

The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin

1 reference

PubMed

12 December 2020

10.1038/NRCLINONC.2010.175

Identifiers

DOI

1 reference

23 August 2017

1 reference